Multi-Target Tyrosine Kinase Inhibitors for Tumor Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperproliferative diseases, such as cancers, often fail to effectively inhibit protein tyrosine kinase activity, particularly in pathways involving VEGF, HGF, and IGF receptors, which are crucial for tumor growth and angiogenesis.
Innovation Solution
Development of novel compounds that inhibit protein tyrosine kinase activity, specifically targeting VEGF receptor KDR, HGF receptor c-Met, and IGF1R, with specific chemical structures capable of simultaneously inhibiting these receptors, thereby disrupting key signaling pathways involved in tumor growth and angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to target protein tyrosine kinase activity, then some inhibition effect is achieved, but the inhibition is insufficient particularly in pathways involving VEGF, HGF, and IGF receptors
Solution Approach 1:
The patent describes compounds that simultaneously inhibit multiple receptor tyrosine kinases including VEGF receptors (KDR, FLT1), HGF receptor (c-Met), and IGF1R. This multi-functional inhibitor approach allows a single compound to target multiple critical pathways involved in tumor growth and angiogenesis, thereby improving both inhibition effectiveness and multi-receptor coverage without requiring separate treatments for each pathway.
2Adaptability or versatility
If specific chemical structures are designed to simultaneously inhibit multiple receptors, then multi-receptor coverage is improved, but the structural complexity increases
Solution Approach 1:
The patent combines multiple pharmacophoric elements into a single molecular structure that can interact with multiple receptor tyrosine kinases. The compound integrates structural features that enable binding to VEGF receptors, HGF receptor, and IGF1R simultaneously, merging the functionality of what would traditionally require multiple separate molecules into one unified structure, thereby achieving multi-receptor coverage while managing structural complexity.
3Reliability
If novel compounds are developed to target multiple kinase pathways, then therapeutic efficacy is improved, but the development complexity and time increase
Solution Approach 1:
The patent employs rational drug design based on known structures of receptor tyrosine kinases and their ligands. By preliminarily analyzing the binding pockets and key interaction residues of VEGF receptors, HGF receptor, and IGF1R, the researchers designed compounds with pre-optimized structures that target multiple receptors simultaneously. This preliminary structural analysis and design approach accelerates the development process compared to traditional trial-and-error methods, reducing development time while maintaining high therapeutic efficacy.
Data Source
AI summary
The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.